Intervention

topotecan

ClinicalTrials.gov intervention label

Clinical trials10

Recruiting0

Common conditions10

Lead sponsors shown4

Clinical trials

10 shown

Brain Metastases In ErbB2-Positive Breast CancerNCT00437073 · 2007-05-01

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung CancerNCT00397293 · 2006-11-01

Topotecan in Combination With Pemetrexed in Patients With Advanced MalignanciesNCT00315861 · 2006-03-01

First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And ParaplatinNCT00316186 · 2005-06-01

A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid TumorsNCT00259935 · 2004-10-04

Topotecan for Irinotecan-Refractory SCLCNCT00502762 · 2004-09-01

The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)NCT00043862 · 2002-08-01

Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung CancerNCT00049998 · 2001-10-01

A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid TumorsNCT00046111 · 2001-09-01

Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung CancerNCT00276276 · 2000-11-01

Common conditions

Lung Cancer, Small Cell5 Lung Cancer2 Small Cell Lung Cancer2 Cervical Cancer1 Endometrial Cancer1 Neoplasms, Breast1 Non-Small-Cell Lung Cancer1 Ovarian Cancer1 Refractory to Chemotherapy1 Solid Tumor Cancer1

Leading sponsors

GlaxoSmithKline7 Ascenta Therapeutics1 Gachon University Gil Medical Center1 SCRI Development Innovations, LLC1

Trial status mix

COMPLETED8

TERMINATED1

UNKNOWN1

Phase mix

PHASE25

PHASE14

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.